TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* all women who underwent a Roux-en-Y gastric bypass and developed an iron deficiency postoperatively (ferritin\<20microgram/L)~Exclusion Criteria:~* iron deficiency peroperative, blood transfusions during study period, iron containing nutritional supplements except the standard multivitamins after bariatric surgery, decreased renal failure, excessive blood loss due to menstruation, anemia not caused by iron deficiency, accumulation of iron, hypersensitivity for noe of the medicinal products, psychiatric illness, pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ferrous fumarate (Type: ACTIVE_COMPARATOR): 40 patients receive ferrous fumarate 3 times a day 200mg
- Ferrous gluconate (Type: ACTIVE_COMPARATOR): 40 patients receive ferrous gluconate 2 times a day 695 mg
- Iron(III)carboxymaltose (Type: ACTIVE_COMPARATOR): 40 patients receive a single intravenous shot of ferinject

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Obstructive sleep apnea syndrome, successfully on CPAP therapy~* Residence at low altitude (\<800m)~* Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy.~* \>15 oxygen desaturations/h (\>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP~Exclusion Criteria:~* Sleep disorders other than OSA.~* More than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease.~* Any lung disease, pulmonary hypertension.~* Chronic rhinitis.~* Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)~* Internal, neurologic or psychiatric disease that interfere with sleep quality.~* Previous intolerance to moderate or low altitude (\<2600m).~* Exposure to altitudes \>1500m for \>1 day within the last 4 weeks before the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* able and willing to give informed consent.~* man or woman of any race and 18 to 55 years of age, inclusive.~* Body Mass Index of 20-30 kg/m2~* willing and able to attend required study visits.~* bilateral visual acuity \>6/10.~* intraocular pressure (IOP) of 14-21 mmHg.~* ophthalmologic examination without abnormalities.~* medical history without major pathology.~* laboratory test results without deviations from the normal range.~* female subjects of childbearing potential with negative urine pregnancy test and using effective contraception during the study.~Exclusion Criteria:~* presence of bacterial ocular infections.~* presence of any concomitant ocular pathology.~* performing activities likely to result in an irritated conjunctiva during the study (including heavy alcohol intake, swimming in chlorinated water and heavy smoking).~* contact lenses wearing .~* ocular surface fluorescein staining score \>3.~* use of topical or systemic antibiotics, antihistamines, decongestants and non-steroidal anti-inflammatory agents as well as steroids within 7 days before screening.~* known or suspected allergy to biguanides or intolerance to any other ingredient of the test treatments.~* ocular surgery performed within 12 months before screening.~* participation in another clinical study in the preceding 30 days.~* one functional eye.~* pregnancy or breastfeeding.~* use of recreational drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 0.04% PHMB (Type: EXPERIMENTAL): 0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
- 0.06% PHMB (Type: EXPERIMENTAL): 0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
- 0.08% PHMB (Type: EXPERIMENTAL): 0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
- PHMB Vehicle (Type: PLACEBO_COMPARATOR): PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with chronic asthma who actively smoke at least 0.5 to no more than 2 packs of cigarettes a day~Exclusion Criteria:~* Participant cannot have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or emphysema.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: Montelukast
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: Fluticasone
- 3 (Type: PLACEBO_COMPARATOR): Arm 3: Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmed advanced well differentiated typical and atypical carcinoid tumors of the lung or thymus~* Patients of all treatment lines including naive patients could have been enrolled~* At least one measurable lesion of disease on CT scan or MRI~* Radiological documentation of disease progression within 12 months prior to randomization~* Adequate liver, renal and bone marrow function~* WHO Performance Status 0-2~Exclusion Criteria:~* Poorly differentiated neuroendocrine carcinoma~* Non-neuroendocrine thymoma~* Patients with severe functional disease who required symptomatic treatment with somatostatin analogs~* Prior therapy with mTOR inhibitors~* History of liver disease~* Baseline QTcF\> 470 msec~* Uncontrolled diabetes mellitus despite adequate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pasireotide LAR (Type: EXPERIMENTAL): Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
- Everolimus (Type: EXPERIMENTAL): Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
- Pasireotide LAR and Everolimus Combination (Type: EXPERIMENTAL): Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
\* Eligibility Criteria： Inclusion Criiteria:~1. Male or female 18 to 75 years of age at the time of consent.~2. T2D patients with poorly controlled blood glucose treated with lifestyle intervention or stable dose of metformin (≥ 1000mg/day or maximum tolerated dose) within 2 months prior to screening.~3. HbA1c 7.5% ≤ 11.0% by local laboratory at screening.~4. Body mass index 20 ≤ BMI ≤ 35 kg/m2.~Exclusion Criteria:~1. Type 1 diabetes, special types of diabetes, or gestational diabetes.~2. Ketoacidosis or lactic acidosis within 6 months prior to screening.~3. History of severe hypoglycaemic episodes within 6 months prior to screening.~4. Acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, coronary intervention (except diagnostic angiography), transient ischemic attack (TIA), cerebrovascular accident, acute and chronic heart failure within 6 months before screening.~5. Clinically symptomatic liver disease, acute or chronic hepatitis, or transaminases (ALT and AST) and alkaline phosphatase (ALP) \> 2 times the upper limit of normal and total bilirubin above the upper limit of normal at screening.~6. The patient was previously diagnosed with autonomic neuropathy, manifested as urinary retention, resting tachycardia, orthostatic hypotension and diabetic diarrhea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI362 low dose cohort (Type: EXPERIMENTAL): Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.
- IBI362 medium dose cohort (Type: EXPERIMENTAL): Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
- IBI362 high dose cohort (Type: EXPERIMENTAL): Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Obesity and Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All~* 18 - 45 years old~* Class I obesity, i.e. Body Mass Index (BMI) between 30 and 45.~* weight less than 300 lbs.~Exclusion Criteria:~* Active or previous infection with hepatitis B or C, as well as other liver disease.~* History of alcohol abuse~* Diabetes~* Medications that cause liver damage or steatosis.~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- NAFLD-Niacin (Type: EXPERIMENTAL): Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
- Control (Type: NO_INTERVENTION): Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
- NAFLD-fenofibrate (Type: EXPERIMENTAL): Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
- NAFLD-placebo (Type: PLACEBO_COMPARATOR): These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA Ι and II.~2. Both males and females, age (18-60) years.~3. Supine position.~4. Glasco coma scale more than 12.~5. Elective craniotomy operations.~Exclusion Criteria:~1. ASA ΙII or IV~2. History of allergy to the study drugs.~3. Surgery to remove pituitary tumours or affecting pituitary hormones.~4. Glasco coma scale less than 12.~5. The need for postoperative ventilation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group H (Hyaluronidase added to local anaesthetics) (Type: ACTIVE_COMPARATOR): group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve
- Group A (local anaesthetics alone) (Type: ACTIVE_COMPARATOR): Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Misoprostol on Blood Loss In Myomectomy Operations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal patients aged between 35 to 50 years old.~* Five or less symptomatic uterine myomas .~* Maximum diameter of the largest myoma is 6 cm .~* All myomas are subserous or intramural.~* Uterine size less than 24 weeks pregnancy~Exclusion Criteria:~* History of previous surgery.~* Allergy to Misoprostol.~* Hypertension.~* Cardiac and Pulmonary diseases.~* Patients who have bleeding disorders.~* Anemia (Hb \< 10g %).~* Chronic endocrine or metabolic diseases such as Diabetes.~* Obesity (body mass index \> 30 kg/m2).~* Cases that will require intraoperative conversion of myomectomy to hysterectomy.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Myomectomy, rectal Misoprostol (Type: EXPERIMENTAL): 25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
- Myomectomy, Placebo (Type: ACTIVE_COMPARATOR): Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient suffering from:~* acute leukemia with white blood cell (WBC) count≥ 20,000/mm3 without regard to uric acid level ; or~* lymphoma,Stage ≥ III without regard to uric acid level; or~* lymphomas, Stage II with bulky disease; or~* lymphoma or leukemia, without regard to classification or morphology, with uric acid level ≥ 8.0 mg/dL, and lactate dehydrogenase (LDH) level ≥ twice the upper limit of normal (ULN).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemini Symbicort pMDI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of asthma~* Baseline lung function tests as determined by protocol.~* Required and received treatment with inhaled corticosteroids and/or lung treatments specified in the protocol within timeframe and doses specified in protocol.~Exclusion Criteria:~* Severe asthma~* Has required treatment with any non-inhaled corticosteroid within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers~* Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease within 16 weeks prior to Screening~* Mean Screening hemoglobin between 8.0 and \<11.0 grams per deciliter (g/dL) (inclusive)~* Serum ferritin ≥100 nanograms per deciliter (ng/mL) and TSAT ≥20% during Screening~Exclusion Criteria:~* Anemia due to a cause other than chronic kidney disease or participants with active bleeding or recent blood loss~* Red blood cells transfusion within 8 weeks prior to randomization~* Anticipated to recover adequate kidney function to no longer require dialysis~* Uncontrolled hypertension~* Severe heart failure at Screening (New York Heart Association Class IV)~* Acute coronary syndrome (hospitalization for unstable angina, myocardial infarction); surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity); surgical or percutaneous valvular replacement or repair; sustained ventricular tachycardia; hospitalization for congestive heart failure; or stroke within 12 weeks prior to or during Screening.~* Participants meeting the criteria of erythropoiesis-stimulating agent resistance within 8 weeks prior to or during Screening defined as follows~  1. epoetin: \> 7700 units/dose three times per week or \>23,000 units per week~ 2. Darbepoetin alfa: \>100 micrograms per week (mcg/week)~ 3. methoxy polyethylene glycol-epoetin beta: \>100 micrograms (mcg) every other week or \>200 mcg/month~* Hypersensitivity to Vadadustat, Darbepoetin alfa or any of their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vadadustat (Type: EXPERIMENTAL): None
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Variance Throughout the Day

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are a healthy male or female~* Have a fasting blood sugar that is between normal and diabetes.~* Are between 18 and 70 years of age, inclusive.~Exclusion Criteria:~* Are pregnant or breast-feeding a child~* Take a medication for diabetes~* Take a medication like cortisone that can change your blood sugar.~* Take a medication chronically that has not been at a stable dose for at least 1 month~* Take medication for psychosis that is known to change timing in the day - night cycle

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Insulin Sensitivity in Pre-Diabetic Population (Type: None): Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete